The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus
- 1 November 2020
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 45 (12) , 2106-2113
Abstract
The group 2 metabotropic glutamate receptor (mGluR2/3) agonist, pomaglumetad methionil (POM), showed promise as a novel antipsychotic in preclinical research but failed to show efficacy in clinical trials, though it has been suggested that it may be effective in certain patient populations. Although previous studies have shown that mGluR2/3 agonists have no effect on dopamine (DA) in wild type rats, we used the methylzoxymethanol acetate (MAM) model to determine whether POM may indirectly normalize DA neuron activity in a model representative of the hyperdopaminergic state thought to underlie psychosis, compared to SAL rats, using in vivo, anesthetized, electrophysiological recordings. POM dose-dependently reduced the number of spontaneously active DA neurons in the VTA of MAM rats to control levels without affecting DA firing in SAL rats, which persisted following 14d repeated treatment with POM. In female MAM rats, POM significantly reduced DA neuron population activity only during proestrous and estrous stages. MAM rats also demonstrated dose-dependent improvement in novel object recognition following acute POM, which was not observed in SAL rats. Similar to the MAM rats, DA neuron population activity was increased in a hippocampal-dependent manner following acute restraint stress. Administration of POM prior to 2 h restraint stress prevented the restraint-induced increase in DA neuron population activity, and this effect was blocked by pretreatment with an mGluR2/3 antagonist. Thus, the ability of POM to reduce the hyperdopaminergic activity in both MAM rats and in wild type rats following restraint stress suggests that it can indirectly regulate DA neuron activity, which may underlie its potential therapeutic effects.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH57440)
This publication has 75 references indexed in Scilit:
- A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophreniaBMC Psychiatry, 2013
- Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophreniaTrends in Pharmacological Sciences, 2011
- Hippocampal interneurons are abnormal in schizophreniaSchizophrenia Research, 2011
- Antipsychotic Drugs Rapidly Induce Dopamine Neuron Depolarization Block in a Developmental Rat Model of SchizophreniaJournal of Neuroscience, 2011
- A Novel α5GABAAR-Positive Allosteric Modulator Reverses Hyperactivation of the Dopamine System in the MAM Model of SchizophreniaNeuropsychopharmacology, 2011
- Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET studyMolecular Psychiatry, 2011
- Long-term Antipsychotic Treatment and Brain VolumesArchives of General Psychiatry, 2011
- Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotionPsychopharmacology, 2010
- NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal NeuronsThe Journal of Neuroscience, 2007
- A Systematic Review of the Prevalence of SchizophreniaPLOS Medicine, 2005